Expression of Concern: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma
Pathol Oncol Res. 2023 Nov 9;29:1611563. doi: 10.3389/pore.2023.1611563. eCollection 2023.ABSTRACT[This corrects the article DOI: 10.3389/pore.2023.1611204.].PMID:38025906 | PMC:PMC10666178 | DOI:10.3389/pore.2023.1611563 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
Conclusion: We confirm that low dose of vemurafenib is effective and safe in the vast majority of patients with HCL. This small-molecule oral treatment allows to gain valuable time-months or even years-before further, usually parenteral treatment options have to be given or before previous treatment has to be repeated. There are also promising data supporting the combination of vemurafenib with other drugs for the treatment of HCL patients which could provide even further possibility to bridge treatment.PMID:38025907 | PMC:PMC10663343 | DOI:10.3389/pore.2023.1611378 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Kata Ferenczi Zs ófia Flóra Nagy Ildik ó Istenes Hanna Eid Csaba B ödör Botond Tim ár Judit Demeter Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Expression of Concern: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma
Pathol Oncol Res. 2023 Nov 9;29:1611563. doi: 10.3389/pore.2023.1611563. eCollection 2023.ABSTRACT[This corrects the article DOI: 10.3389/pore.2023.1611204.].PMID:38025906 | PMC:PMC10666178 | DOI:10.3389/pore.2023.1611563 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
Conclusion: We confirm that low dose of vemurafenib is effective and safe in the vast majority of patients with HCL. This small-molecule oral treatment allows to gain valuable time-months or even years-before further, usually parenteral treatment options have to be given or before previous treatment has to be repeated. There are also promising data supporting the combination of vemurafenib with other drugs for the treatment of HCL patients which could provide even further possibility to bridge treatment.PMID:38025907 | PMC:PMC10663343 | DOI:10.3389/pore.2023.1611378 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Kata Ferenczi Zs ófia Flóra Nagy Ildik ó Istenes Hanna Eid Csaba B ödör Botond Tim ár Judit Demeter Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Expression of Concern: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma
Pathol Oncol Res. 2023 Nov 9;29:1611563. doi: 10.3389/pore.2023.1611563. eCollection 2023.ABSTRACT[This corrects the article DOI: 10.3389/pore.2023.1611204.].PMID:38025906 | PMC:PMC10666178 | DOI:10.3389/pore.2023.1611563 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
Conclusion: We confirm that low dose of vemurafenib is effective and safe in the vast majority of patients with HCL. This small-molecule oral treatment allows to gain valuable time-months or even years-before further, usually parenteral treatment options have to be given or before previous treatment has to be repeated. There are also promising data supporting the combination of vemurafenib with other drugs for the treatment of HCL patients which could provide even further possibility to bridge treatment.PMID:38025907 | PMC:PMC10663343 | DOI:10.3389/pore.2023.1611378 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Kata Ferenczi Zs ófia Flóra Nagy Ildik ó Istenes Hanna Eid Csaba B ödör Botond Tim ár Judit Demeter Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Expression of Concern: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma
Pathol Oncol Res. 2023 Nov 9;29:1611563. doi: 10.3389/pore.2023.1611563. eCollection 2023.ABSTRACT[This corrects the article DOI: 10.3389/pore.2023.1611204.].PMID:38025906 | PMC:PMC10666178 | DOI:10.3389/pore.2023.1611563 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
Conclusion: We confirm that low dose of vemurafenib is effective and safe in the vast majority of patients with HCL. This small-molecule oral treatment allows to gain valuable time-months or even years-before further, usually parenteral treatment options have to be given or before previous treatment has to be repeated. There are also promising data supporting the combination of vemurafenib with other drugs for the treatment of HCL patients which could provide even further possibility to bridge treatment.PMID:38025907 | PMC:PMC10663343 | DOI:10.3389/pore.2023.1611378 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Kata Ferenczi Zs ófia Flóra Nagy Ildik ó Istenes Hanna Eid Csaba B ödör Botond Tim ár Judit Demeter Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Expression of Concern: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma
Pathol Oncol Res. 2023 Nov 9;29:1611563. doi: 10.3389/pore.2023.1611563. eCollection 2023.ABSTRACT[This corrects the article DOI: 10.3389/pore.2023.1611204.].PMID:38025906 | PMC:PMC10666178 | DOI:10.3389/pore.2023.1611563 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
Conclusion: We confirm that low dose of vemurafenib is effective and safe in the vast majority of patients with HCL. This small-molecule oral treatment allows to gain valuable time-months or even years-before further, usually parenteral treatment options have to be given or before previous treatment has to be repeated. There are also promising data supporting the combination of vemurafenib with other drugs for the treatment of HCL patients which could provide even further possibility to bridge treatment.PMID:38025907 | PMC:PMC10663343 | DOI:10.3389/pore.2023.1611378 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Kata Ferenczi Zs ófia Flóra Nagy Ildik ó Istenes Hanna Eid Csaba B ödör Botond Tim ár Judit Demeter Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
